Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines

DNA and Cell Biology

Volumn 31, Issue 1, 2012, Pages 15-29

  Kim, Young Mee ^a   Pyo, Hongryull ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATR PROTEIN; CELECOXIB; HEAT SHOCK PROTEIN 90; TANESPIMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2 INHIBITORS; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG SYNERGISM; HCT116 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; LACTAMS, MACROCYCLIC; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; RADIOTHERAPY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ATAXIA TELANGIECTASIA;

EID: 84855450333     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2011.1342     Document Type: Article

References (33)

1. Berenbaum, M.C. (1978). A method for testing for synergy with any number of agents. J Infect Dis 137, 122-130. (Pubitemid 8289152)
2. Chistiakov, D.A., Voronova, N.V., and Chistiakov, P.A. (2008). Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients. Acta Oncol 47, 809-824. (Pubitemid 351882749)
3. Chou, T.C. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58, 621-681.
4. Davies, N.M., McLachlan, A.J., Day, R.O., and Williams, K.M. (2000). Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38, 225-242. (Pubitemid 30156623)
5. Dittmann, K.H., Mayer, C., Ohneseit, P.A., Raju, U., Andratschke, N.H., Milas, L., and Rodemann, H.P. (2008). Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Int J Radiat Oncol Biol Phys 70, 203-212. (Pubitemid 350251053)
6. Enmon, R., Yang, W.H., Ballangrud, A.M., Solit, D.B., Heller, G., Rosen, N., Scher, H.I., and Sgouros, G. (2003). Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res 63, 8393-8399. (Pubitemid 37549494)
7. Fracasso, P.M., et al. (2011). A phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 67, 1225-1237.
8. Greco, W.R., Bravo, G., and Parsons, J.C. (1995). The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47, 331-385.
9. Jun, H.J., Kim, Y.M., Park, S.Y., Park, J.S., Lee, E.J., Choi, S.A., and Pyo, H. (2009). Modulation of ionizing radiation-induced G2 arrest by cyclooxygenase-2 and its inhibitor, Celecoxib. Int J Radiat Oncol Biol Phys 75, 225-234.
10. Kim, Y.M., Lee, E.J., Park, S.Y., Cho, K.H., Kim, J.Y., and Pyo, H. (2009). Cyclooxygenase-2 up-regulates ataxia telangiectasia and Rad3 related through extracellular signal-regulated kinase activation. Mol Cancer Res 7, 1158-1168.
11. Kobayashi, S., Nantz, R., Kitamura, T., Higashikubo, R., and Horikoshi, N. (2005). Combined inhibition of extracellular signal-regulated kinases and HSP90 sensitizes human colon carcinoma cells to ionizing radiation. Oncogene 24, 3011-3019. (Pubitemid 40675532)
12. McClellan, A.J., Xia, Y., Deutschbauer, A.M., Davis, R.W., Gerstein, M., and Frydman, J. (2007). Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 131, 121-135. (Pubitemid 47498528)
13. Modi, S., et al. (2007). Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25, 5410-5417. (Pubitemid 350232217)
14. Neckers, L. (2007). Heat shock protein 90: the cancer chaperone. J Biosci 32, 517-530. (Pubitemid 46708702)
15. Neuhofer, W., Holzapfel, K., Fraek, M.L., Ouyang, N., Lutz, J., and Beck, F.X. (2004). Chronic COX-2 inhibition reduces medullary HSP70 expression and induces papillary apoptosis in dehydrated rats. Kidney Int 65, 431-441. (Pubitemid 38130637)
16. Nomura, M., Nomura, N., and Yamashita, J. (2005). Geldanamycin-induced degradation of Chk1 is mediated by proteasome. Biochem Biophys Res Commun 335, 900-905. (Pubitemid 41188281)
17. On, K.F., Chen, Y., Ma, H.T., Chow, J.P.H., and Poon, R.Y.C. (2011). Determinants of mitotic catastrophe upon abrogation of the G2 DNA damage checkpoint by UCN-01. Mol Cancer Ther 10, 784-794.
18. Park, J.S., Jun, H.J., Cho, M.J., Cho, K.H., Lee, J.S., Zo, J.I., and Pyo, H. (2006). Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells. Clin Cancer Res 12, 4989-4999. (Pubitemid 44338588)
19. Peterson, J.J., and Novick, S.J. (2007). Nonlinear blending: a useful general concept for the assessment of combination drug synergy. J Recept Signal Transduct Res 27, 125-146. (Pubitemid 47024328)
20. Powers, M.V., Clarke, P.A., and Workman, P. (2008). Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 14, 250-262.
21. Powers, M.V., and Workman, P. (2006). Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 13 Suppl 1, S125-S135. (Pubitemid 46219254)
22. Powers, M.V., and Workman, P. (2007). Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 581, 3758-3769. (Pubitemid 47081010)
23. Prise, K.-M., and O'Sullivan, J.-M. (2009). Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer 9, 351-360.
24. Pyo, H., Choy, H., Amorino, G.P., Kim, J., Cao, Q., Hercules, S.K., and DuBois, R.N. (2001). A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 7, 2998-3005. (Pubitemid 32963816)
25. Sauvageot, C.M., et al. (2009). Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol 11, 109-121.
26. Shin, Y.K., Park, J.S., Kim, H.S., Jun, H.J., Kim, G.E., Suh, C.O., Yun, Y.S., and Pyo, H. (2005). Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 65, 9501-9509. (Pubitemid 41508020)
27. Stravopodis, D.J., Margaritis, L.H., and Voutsinas, G.E. (2007). Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr Med Chem 14, 3122-3138. (Pubitemid 350226961)
28. Steel, G.G., and Peckham, M.J. (1979). Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5, 85-91. (Pubitemid 9120186)
29. Tse, A.N., Carvajal, R., and Schwartz, G.K. (2007). Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 13, 1955-1960. (Pubitemid 46649860)
30. Tse, A.N., Sheikh, T.N., Alan, H., Chou, T.C., and Schwartz, G.K. (2009). 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Mol Pharmacol 75, 124-133.
31. Tsutsumi, S., Scroggins, B., Koga, F., Lee, M.J., Trepel, J., Felts, S., Carreras, C., and Neckers, L. (2008). A small molecule cellimpermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 27, 2478-2487. (Pubitemid 351521101)
32. Yano, A., Tsutsumi, S., Soga, S., Lee, M.J., Trepel, J., Osada, H., and Neckers, L. (2008). Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci U S A 105, 15541-15546.
33. Zhao, R., et al. (2005). Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 120, 715-727. (Pubitemid 40343082)